TY - JOUR T1 - Elevated plasma Complement Factor H Regulating Protein 5 is associated with venous thromboembolism and COVID-19 severity JF - medRxiv DO - 10.1101/2022.04.20.22274046 SP - 2022.04.20.22274046 AU - Laura Sanchez-Rivera AU - Maria Jesus Iglesias AU - Manal Ibrahim-Kosta AU - Julia Barbara Kral-Pointner AU - Sebastian Havervall AU - Louisa Goumidi AU - Maria Farm AU - Gaëlle Munsch AU - Marine Germain AU - Philip Smith AU - Mun-Gwan Hong AU - Pierre Suchon AU - Clément Naudin AU - Anne Boland AU - David M Smadja AU - Margareta Holmström AU - Maria Magnusson AU - Angela Silveira AU - Mathias Uhlén AU - Thomas Renné AU - Angel Martinez-Perez AU - Joseph Emmerich AU - Jean-Francois Deleuze AU - Jovan Antovic AU - Alice Assinger AU - Jose Manuel Soria Fernandez AU - Charlotte Thålin AU - Jochen M Schwenk AU - Juan Carlos Souto Andres AU - Pierre-Emmanuel Morange AU - Lynn Marie Butler AU - David-Alexandre Trégouët AU - Jacob Odeberg Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/04/21/2022.04.20.22274046.abstract N2 - Venous thromboembolism (VTE), comprising both deep vein thrombosis (DVT) and pulmonary embolism (PE) is a common, multi-causal disease with potentially serious short- and long-term complications. In clinical practice, there is a need for improved plasma biomarker-based tools for VTE diagnosis and risk prediction. We used multiplex proteomics profiling to screen plasma from patients with suspected acute VTE, and a case-control study of patients followed up after ending anticoagulant treatment for a first VTE. With replication in 5 independent studies, together totalling 1137 patients and 1272 controls, we identify Complement Factor H Related Protein (CFHR5), a regulator of the alternative pathway of complement activation, as a novel VTE associated plasma biomarker. Using GWAS analysis of 2967 individuals we identified a genome-wide significant pQTL signal on chr1q31.3 associated with CFHR5 levels. We showed that higher CFHR5 levels are associated with increased thrombin generation in patient plasma and that recombinant CFHR5 enhances platelet activation in vitro. Thrombotic complications are a frequent feature of COVID-19; in hospitalised patients we found CFHR5 levels at baseline were associated with short-time prognosis of disease severity, defined as maximum level of respiratory support needed during hospital stay. Our results indicate a clinically important role for regulation of the alternative pathway of complement activation in the pathogenesis of VTE and pulmonary complications in acute COVID-19. Thus, CFHR5 is a potential diagnostic and/or risk predictive plasma biomarker reflecting underlying pathology in VTE and acute COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was supported by grants from Stockholm City Council (SLL) to JO (2017-0842/0587, 2020-0346), from Familjen Erling Personssons Stiftelse to MU, Knut och Alice Wallenberg foundation to JO (2020.0182, 2020.0241), from Swedish Heart Lung Foundation to LB (20170759, 20170537), National Research Council (VR) to LB (2019-01493), HelseNord to JO (HNF1544-20). The Human Protein Atlas (HPA) is funded by The Knut and Alice Wallenberg Foundation. MARTHA and FARIVE related genetics research programs were funded by the GENMED Laboratory of Excellence on Medical Genomics [ANR-10-LABX-0013], a research program managed by the National Research Agency (ANR) as part of the French Investment for the Future, and supported by the French INvestigation Network on Venous Thrombo-Embolism (INNOVTE). MARTHA and FARIVE genetic data analyses benefit from the technical support of the CBiB computing centre of the University of Bordeaux. GM and D-AT are supported by the EPIDEMIOM-VT Senior Chair from the University of Bordeaux initiative of excellence IdEX. GM benefited from the EUR DPH, a PhD program supported within the framework of the PIA3 (Investment for the future). Project reference 17-EURE-0019. The RETROVE study was supported by grants PI12/00612 and PI15/0026. Genotyping of the RETROVE samples was supported by grant PT17/0019, of the PE I+D+i 2013-2016, funded by ISCIII and ERDF. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The following Ethics Committees/IRBs gave ethical approvals for this work: The regional research ethics review board in Stockholm, Sweden, gave ethical approval for the VEBIOS study(KI 2010/636-31/4) and the DFW-VTE study (DNR 2013-2143-31-2. The National Ethical Board of Sweden gave ethical approval for the COMMUNITY study(EPM 2020‐01653). The Paris Broussais-HEGP ethics committee in Paris gave ethical approval for the FARIVE study(2002-034). The Department of Health and Science, France (2008-880 & 09.576) gave ethical approval for the MARTHA study. The Institutional Review Board of the Hospital de la Santa Creu i Sant Pau, gave ethical approval for the RETROVE study. The Human Ethics Committee of the Medical University of Vienna gave ethical approval for the platelet activation work(EK237/2004) I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors following review of alignment with ethical permits. ER -